Peptide supply chain: difference between revisions
Diff·revision 16 → 17·04:13, 10 Apr 2025
Difference between revision 16 and revision 17 of Peptide supply chain. 4 lines changed; the page grew by 894 bytes.
| Revision 16 — 16:12, 22 Mar 2025 CouplingCillian (talk) add the stopper material, since it affects moisture ingress 6,060 bytes ±0 | Revision 17 — 04:13, 10 Apr 2025 Hedgerow_Hal (talk) give the closure integrity test by name 6,954 bytes +894 | ||
|---|---|---|---|
| 39 | Two common arrangements lengthen that interval. In a '''regional warehouse''' model, material is manufactured, released, shipped in bulk to a warehouse in the destination region, and held there until ordered. The transit the purchaser sees is short; the total interval since release may be months, and nothing in the documentation states either the interval or the storage conditions during it. In a '''repackaging''' model, bulk material is subdivided into vials by a party other than the manufacturer, and the certificate describes the bulk rather than the vial.{{r|usp1503,reports}} | 39 | Two common arrangements lengthen that interval. In a '''regional warehouse''' model, material is manufactured, released, shipped in bulk to a warehouse in the destination region, and held there until ordered. The transit the purchaser sees is short; the total interval since release may be months, and nothing in the documentation states either the interval or the storage conditions during it. In a '''repackaging''' model, bulk material is subdivided into vials by a party other than the manufacturer, and the certificate describes the bulk rather than the vial.{{r|usp1503,reports}} |
| 40 | 40 | ||
| + | 41 | Neither arrangement is improper and both have straightforward commercial reasons — a regional warehouse is why delivery inside a served region takes days rather than weeks. Where a determination is repeated after storage, the laboratory repeating it is assessed on its own competence and not on the history of what it was sent.{{r|iso17025}} The point is documentary: '''a purchaser who wants to know the interval has to ask for it''', because it is recorded against the lot in the seller's records and does not appear on the certificate. The supplier articles on this wiki record, under §Ordering and availability, which model each organisation operates and what to request accordingly. | |
| + | 42 | ||
| 41 | === Why the interval matters === | 43 | === Why the interval matters === |
| 42 | Degradation in a lyophilised peptide is slow at recommended storage temperatures and is not slow at ambient ones, and the relevant chemistry — [[Deamidation|deamidation]], oxidation, [[Peptide aggregation|aggregation]] — is time-and-temperature dependent rather than time dependent alone.{{r|usp1503}} | 44 | Degradation in a lyophilised peptide is slow at recommended storage temperatures and is not slow at ambient ones, and the relevant chemistry — [[Deamidation|deamidation]], oxidation, [[Peptide aggregation|aggregation]] — is time-and-temperature dependent rather than time dependent alone.{{r|usp1503}} |
| ⋮ | ⋮ | ||
| 49 | <ref name="reports">Purchaser-submitted reports and accompanying documentation held by PeptidePedia, 2024–2026, including descriptions of dispatch origin and packaging. A self-selected sample.</ref> | 51 | <ref name="reports">Purchaser-submitted reports and accompanying documentation held by PeptidePedia, 2024–2026, including descriptions of dispatch origin and packaging. A self-selected sample.</ref> |
| 50 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. Sets out the stage-by-stage controls that unregulated supply is not obliged to operate.</ref> | 52 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. Sets out the stage-by-stage controls that unregulated supply is not obliged to operate.</ref> |
| + | 53 | <ref name="iso17025">ISO/IEC 17025:2017, ''General requirements for the competence of testing and calibration laboratories''. International Organization for Standardization.</ref> | |
| 51 | 54 | ||
| 52 | == See also == | 55 | == See also == |
| ⋮ | ⋮ | ||
| 56 | * [[Certificate of analysis]] | 59 | * [[Certificate of analysis]] |
| 57 | * [[Lot traceability]] | 60 | * [[Lot traceability]] |
| + | 61 | * [[Peptide content]] | |
| 58 | 62 | ||
| 59 | {{DEFAULTSORT:Peptide supply chain}} | 63 | {{DEFAULTSORT:Peptide supply chain}} |